Ajanta Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Yogesh Agrawal

Amministratore delegato

₹216.0m

Compenso totale

Percentuale dello stipendio del CEO	57.2%
Mandato del CEO	16.9yrs
Proprietà del CEO	14.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yogesh Agrawal rispetto agli utili di Ajanta Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	₹9b
Jun 30 2024	n/a	n/a	₹9b
Mar 31 2024	₹216m	₹124m	₹8b
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹6b
Mar 31 2023	₹156m	₹112m	₹6b
Dec 31 2022	n/a	n/a	₹6b
Sep 30 2022	n/a	n/a	₹7b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹163m	₹94m	₹7b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹128m	₹75m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹5b
Mar 31 2020	₹107m	₹66m	₹5b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹4b
Mar 31 2019	₹99m	₹61m	₹4b
Dec 31 2018	n/a	n/a	₹4b
Sep 30 2018	n/a	n/a	₹5b
Jun 30 2018	n/a	n/a	₹5b
Mar 31 2018	₹44m	₹13m	₹5b

Compensazione vs Mercato: La retribuzione totale di Yogesh ($USD 2.56M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 589.97K ).

Compensazione vs guadagni: La retribuzione di Yogesh è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Yogesh Agrawal (52 yo)

16.9yrs

Mandato

₹215,960,000

Compensazione

Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yogesh Agrawal	MD & Executive Director	24.6yrs	₹215.96m	14.48% ₹ 53.5b
Rajesh Agrawal	Joint MD & Director	11.6yrs	₹215.96m	14.48% ₹ 53.5b
Madhusudan Agrawal	Executive Vice Chairman of the Board	26.9yrs	₹42.04m	Nessun dato
Ramesh Jhawar	Director of Ajanta Pharma USA Inc.	no data	₹25.50m	Nessun dato
Mannalal Agrawal	Chairman of the Board	44.9yrs	₹777.00k	Nessun dato
David Rasquinha	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato
Medha Joshi	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato
Sam Gioskos	Director of Ajanta Pharma Philippines Inc.	no data	Nessun dato	Nessun dato
Suttian Deerpaul	Director of Ajanta Pharma (Mauritius) Ltd.	no data	Nessun dato	Nessun dato
Vinayak Muzumdar	Director of Ajanta Pharma (Mauritius) Ltd.	no data	Nessun dato	Nessun dato
Rajesh Dalal	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato
Simi Thapar	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

6.0yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 532331 sono considerati esperti (durata media dell'incarico 6 anni).

Ajanta Pharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer recently sold ₹20m worth of stock

Executive Vice President recently sold ₹5.9m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Recent updates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 7.1% to ₹2,874

Chief Financial Officer recently sold ₹20m worth of stock

Executive Vice President recently sold ₹5.9m worth of stock

Price target increased by 7.6% to ₹2,664

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Ajanta Pharma Limited Approves Interim Dividend

Second quarter 2023 earnings: EPS misses analyst expectations

Ajanta Pharma Limited to Report Q2, 2023 Results on Nov 03, 2022

Price target increased to ₹1,574

US FDA Announces Inspection of Pharma Limited Dahej Facility

Ajanta Pharma Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q4, 2022 Results on May 10, 2022

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,120,000 shares, representing 1.29% for INR 2,856 million.

Insider recently sold ₹8.1m worth of stock

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share

Second quarter 2022 earnings released: EPS ₹22.64 (vs ₹19.51 in 2Q 2021)

Director of Ajanta Pharma USA Inc. recently sold ₹6.9m worth of stock

Price target increased to ₹2,394

First quarter 2022 earnings released: EPS ₹20.08 (vs ₹16.93 in 1Q 2021)

Price target increased to ₹2,260

Price target increased to ₹2,139

Insider recently sold ₹2.1m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

Insider recently sold ₹1.9m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

New 90-day high: ₹1,831

Insider recently sold ₹14m worth of stock

Revenue and earnings beat expectations

Price target raised to ₹1,857

Third quarter 2021 earnings released: EPS ₹20.41 (vs ₹12.33 in 3Q 2020)

Ajanta Pharma Limited to Report Q3, 2021 Results on Feb 02, 2021

Insider recently sold ₹650k worth of stock

New 90-day high: ₹1,704

Insider recently sold ₹798k worth of stock

Insider recently sold ₹818k worth of stock

New 90-day high: ₹1,678

Insider recently bought ₹3.8m worth of stock

Revenue and earnings beat expectations